Clinical

Dataset Information

0

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors


ABSTRACT: This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

DISEASE(S): Adenocarcinoma,Kras G12r,Gallbladder Carcinoma,Minimal Residual Disease,Colorectal Cancer,Nras G12r,Pancreatic Ductal Adenocarcinoma,Neoplasm, Residual,Ovarian Cancer,Kras G12d,Colon Cancer,Bile Duct Neoplasms,Non-small Cell Lung Cancer,Bile Duct Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Ovarian Neoplasms,Nras G12d,Cholangiocarcinoma

PROVIDER: 2374931 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 8247 | ecrin-mdr-crc
2023-07-31 | GSE238163 | GEO
2015-06-03 | GSE54720 | GEO
2015-06-03 | GSE54719 | GEO
2017-06-17 | GSE98630 | GEO
2011-04-01 | GSE23442 | GEO
2023-01-18 | GSE212658 | GEO
2004-07-27 | GSE1594 | GEO
2023-04-17 | GSE224249 | GEO
2021-11-13 | GSE188587 | GEO